Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study

NCT06088121 is registered in ClinicalTrials.gov with Advanced Technology & Communications as lead sponsor.

NCT NCT06088121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of a ATNC MDD-V1 (TMS With Cognitive Training), for the Treatment of Mild Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study
Lead sponsor
Advanced Technology & Communications
Phase
Not applicable
Overall status
Recruiting
Start date
May 15, 2023
Completion date
June 30, 2027
Enrollment
180 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, brain diseases, central nervous system diseases, dementia, mental disorder, nervous system diseases, neurocognitive disorders, neurodegenerative diseases